Xcorporeal, Inc. (AMEX:XCR)
Historical Stock Chart
From Jun 2019 to Jun 2024
Xcorporeal, Inc. (AMEX:XCR) announced today that Victor Gura M.D., the
Company’s Chief Scientific and Medical
Officer, will deliver two presentations at The American Society of
Nephrology’s (“ASN”)
Renal Week, entitled, “The Wearable Artificial
Kidney (“WAK”)
Removes and Absorbs Uric Acid, Hippuric Acid, Indoxyl Sulphate and
Indole Acetic Acid” and “The
Push Pull, Double Pulsation Flow in Opposite Phase Improves
Ultrafiltration and Convective Transport across the Dialyzer Membrane in
the WAK.” Both of these presentations
continue to demonstrate the feasibility of a fully wearable hemodialysis
device with the potential to effectively remove large molecule toxins.
Dr. Gura will present today at 10.00 a.m. Eastern time. Renal Week is
being held at the Pennsylvania Convention Center in Philadelphia, PA
from November 4th thru November 9th,
2008.
Additionally, Dr. Gura, along with Dr. Claudio Ronco and Dr. Andrew
Davenport, have recently published an article entitled “A
Wearable Artificial Kidney, Dream or Reality”
in the November 2008 issue of Nature Nephrology. The article may be
found at: www.nature.com/ncpneph/journal/v4/n11/full/ncpneph0929.html
Dr. Claudio Ronco is Head of the Department of Nephrology, Dialysis and
Transplantation at St. Bortolo Hospital, Vicenza, Italy and a consultant
to Xcorporeal. Dr. Davenport is a Consultant and Honorary Senior
Lecturer in the University College of London Centre for Nephrology at
the Royal Free & University College Medical School, London, UK.
The ASN is organized and operated exclusively for scientific and
educational purposes, including enhancing the field of nephrology by
advancing the scientific knowledge and clinical practice of that
discipline through stimulation of basic and clinical investigation,
providing access to new knowledge through the publication of journals
and the holding of scientific meetings, advocating for the development
of national health policies to improve the quality of care for renal
patients, cooperating with other national and international societies
and organizations involved in the field of nephrology, and using other
means as directed by the Council of the Society.
About Xcorporeal
Xcorporeal, Inc. is a medical device company developing an innovative extra-corporeal
platform technology to be used in devices to replace the function of
various human organs. The platform leads to three initial products: a
Portable Artificial Kidney (PAK) for hospital based Renal Replacement
Therapy, the XCR-6 for home hemodialysis, and a Wearable Artificial
Kidney (WAK) for continuous ambulatory hemodialysis.
For the hospital market, Xcorporeal is developing a portable,
multi-functional renal replacement device that will offer cost-effective
therapy for those patients suffering from Acute Renal Failure, which
causes a rapid decline in kidney function. In the U.S., the disease
affects more than 200,000 patients annually with a mortality rate
approaching 50%, according to a study published in the Clinical Journal
of American Society of Nephrology in 2006. The Company has completed the
development of the product prototype, which is currently undergoing
bench testing, and anticipates submitting 510(k) filings, for the device
and attendant disposable components, with the Food and Drug
Administration (FDA) during 2009.
The Company also plans to commercialize the XCR-6, a home hemodialysis
device, for the chronic End Stage Renal Disease (ESRD) market, comprised
of patients in whom the kidneys have ceased to function. The Company’s
devices are intended to combine the best attributes of currently
marketed home hemodialysis machines to offer patients convenient,
durable and truly portable treatments at home. The Company believes its
devices will provide a cost-effective alternative to current home
treatment modalities, due to their ability to offer hemodialysis without
the need for large quantities of purified water. The Company has also
completed the development of the XCR-6, which is currently undergoing
bench testing, and anticipates submitting a 510(k) with the FDA during
2010.
The Company’s WAK is also a device for the
chronic treatment of ESRD. The Company has successfully demonstrated a
prototype system that weighs less than 5 kg., is battery operated, and
can be worn by an ambulating patient while undergoing dialysis. This
miniature, wearable device is intended to enable continuous (up to 24
hours × 7 days per week) renal replacement
therapy at home. Human studies with the WAK have been described in
several scientific peer reviewed publications including Lancet and
Kidney International. It was also featured internationally by the
general press including the Los Angeles Times, Le Figaro, Corriere de la
Sera, Frankfurt Algemeiner.
Additional Company information may be found on the Internet at: www.xcorporeal.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this
press release are forward looking and made pursuant to the Safe Harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements reflect numerous assumptions and
involve a variety of risks and uncertainties, many of which are beyond
the company's control that may cause actual results to differ materially
from stated expectations. These risk factors include, among others,
limited operating history, difficulty in developing, exploiting and
protecting proprietary technologies, the risk that our technology may
not be effective, uncertainty as to the outcome of arbitration and legal
proceedings, intense competition and substantial regulation in the
medical device industry; and additional risks factors as discussed in
the reports filed by the Company with the Securities and Exchange
Commission, which are available on its website at http://www.sec.gov.